Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg

International Journal of Clinical Practice

Volumn 70, Issue 3, 2016, Pages 218-221

  Fahrbach, J L ^a   Fu, H ^a   Shurzinske, L ^a   Skrivanek, Z ^a   Martin, S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE; VENOM;

ACCURACY; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; LIRAGLUTIDE; NETWORK META-ANALYSIS; PEPTIDES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VENOMS;

EID: 84959345887     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12775     Document Type: Article

References (21)

1. Buse JB, Nauck M, Forst T, et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381 (9861): 117-24.
2. Pratley RE, Nauck MA, Barnett AH, et al.,; HARMONY 7 Study Group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2 (4): 289-97.
3. Mills EJ, Thorlund K, Ioannidis JP,. Demystifying trial networks and network meta-analysis. BMJ 2013; 346: f2914.
4. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd,; EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13 (5): 418-25.
5. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z,. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29 (10): 1260-7.
6. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z,. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37 (8): 2149-58.
7. Marre M, Shaw J, Brändle M, et al.,; LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26 (3): 268-78.
8. Nauck M, Frid A, Hermansen K, et al.,; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32 (1): 84-90.
9. Garber A, Henry R, Ratner R, et al.,; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373 (9662): 473-81.
10. Zinman B, Gerich J, Buse JB, et al.,; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32 (7): 1224-30.
11. Russell-Jones D, Vaag A, Schmitz O, et al.,; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52 (10): 2046-55.
12. Buse JB, Rosenstock J, Sesti G, et al.,; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374 (9683): 39-47.
13. Pratley R, Nauck M, Bailey T, et al.,; 1860 LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65 (4): 397-407.
14. Wysham C, Bergenstal R, Malloy J, et al., DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28 (6): 705-14.
15. Diamant M, Van Gaal L, Stranks S, et al., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375 (9733): 2234-43.
16. Russell-Jones D, Cuddihy RM, Hanefeld M, et al.,; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35 (2): 252-8.
17. Blevins T, Pullman J, Malloy J, et al., DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96 (5): 1301-10.
18. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Statistics in Practice. Hoboken, NJ: Wiley, 2004.
19. Thomas A, O'Hara B, Ligges U, Sturtz S,. Making BUGS Open. R News 2006; 6 (1): 12-7.
20. Dungan KM, Povedano ST, Forst T, et al., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384 (9551): 1349-57.
21. Wang Y, Fu H, Kulkarni P, Kaiser C,. Evaluating and utilizing probability of study success in clinical development. Clin Trials 2013; 10 (3): 407-13.